FOR IMMEDIATE RELEASE: October 6^th, 2011

Paulsen: Study Confirms Inconsistent FDA Puts Medical Innovation at Risk

Co-Chair of the House Medical Technology Caucus Weighs In on NVCA/MedIC Report

Washington, D.C.– Representative Erik Paulsen (MN-03), co-chair of the House Medical Technology Caucus, issued the following statement in response to a new National Venture Capital Association/Medical Innovation and Competitiveness Coalition surveyconfirming the detrimental effects that the FDA’s inconsistent and unpredictable regulations have on investments in medical innovation.

“All Americans reap the benefits of a robust and innovative medical device and biotechnology industry,” said Rep. Paulsen. “The results of this survey confirm the extent to which many FDA policies hamper this job-creating, and life-saving, industry. I will continue to push for common-sense reforms that encourage innovation and patient safety, and stem the tide against unpredictable and burdensome regulations.”

View Survey Results OnlineHere.

Paulsen, a champion of small business and advocate of free enterprise, entrepreneurship, and innovation currently serves on the House Ways and Means Committee, and is co-chair of the Congressional Korea-U.S. Free Trade Working Group and co-chair of the House Medical Technology Caucus.

For more information on Rep. Paulsen’s work in Congress, please visit www.paulsen.house.gov.

###